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1a,25-Dihydroxyvitamin-D3-3-Bromoacetate
Regulates AKT/mTOR Signaling Cascades:
A Therapeutic Agent for Psoriasis
Ananya Datta Mitra1,2, Siba P. Raychaudhuri1,2, Christine J. Abria2, Anupam Mitra2,3, Rebecca Wright4,
Rahul Ray5 and Smriti Kundu-Raychaudhuri1,2
The efficacy of 1a,25-dihydroxyvitamin D3 (Vit-D) limits its topical use despite its profound effects on cellular
differentiation, proliferation, and immunomodulation. Therefore, in search for a more effective analog of Vit-D,
in this study we have evaluated the antiproliferative and proapoptotic effects of 1a,25-dihydroxyvitamin
D3-3-bromoacetate (BE). Proliferation and apoptosis studies in normal human epidermal keratinocytes (NHEKs)
were conducted by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), CFSE (carboxy fluorescein
succinimidyl ester) dilution, and Annexin V assays. Western blot analysis and real-time PCR were performed to
determine its effect on signal transduction. A reconstructed human epidermis (RHE) model was used to further
validate the therapeutic role of BE in psoriasis. BE was significantly more potent than an equivalent concentration
of Vit-D in inhibiting growth and survival of human keratinocytes. The antimitotic effect was found to be due to
the inhibition of phosphorylation of serine/threonine protein kinase (AKT) and its downstream target,
mammalian target of rapamycin (mTOR). In the RHE model, BE reversed IL-22-induced psoriasiform changes
more effectively than Vit-D. Interestingly, BE inhibited the IL-22-induced gene expression of AKT1, MTOR,
chemokines [IL-8 and RANTES (regulated upon activation, normal T-cell expressed and secreted)], and psoriasin
(S100A7) more significantly than Vit-D. These results suggest the potential of BE as a prospective therapeutic
agent for psoriasis.
Journal of Investigative Dermatology (2013) 133, 1556–1564; doi:10.1038/jid.2013.3; published online 7 March 2013
INTRODUCTION
Psoriasis is a chronic inflammatory disease of the skin involving
a complex interplay of genetic, environmental, and immuno-
logic factors (Gladman et al., 1986; Sakkas et al., 1990;
Henseler, 1997; Raychaudhuri and Gross, 2000). The
pathogenesis of psoriasis involves an interaction of
keratinocytes, T lymphocytes, antigen-presenting cells, and
vascular endothelium (Krueger and Bowcock, 2005; Lowes
et al., 2007) with growth factors such as EGF (Piepkorn et al.,
1998) and soluble factors such as IL-20 subfamily cytokines (IL-
19, IL-20, IL-22, IL-24, and IL-26) (Blumberg et al., 2001;
Rmer et al., 2003; Wolk et al., 2004; Otkjaer et al., 2005).
The 1a,25-dihydroxyvitamin D3 (referred to as Vit-D) and its
analogs modulate the growth of numerous cancer cells by
inhibiting proliferation and promoting differentiation (Jones
et al.,1998). The antiproliferative activity of Vit-D on normal
and psoriatic keratinocytes (Matsumoto et al., 1990; Boisseau-
Garsaud et al., 1996) has been used effectively in topical
treatment of psoriasis (Kowalzick, 2001). It also inhibits IL-8
production in cultured normal epidermal keratinocytes
(NHEKs) and induces apoptosis in psoriatic keratinocytes
(Fukuoka et al., 1998; Tiberio et al., 2009).
A topical Vit-D analog (calcipotriol) has been reported as an
effective and safe treatment for psoriasis (Perez et al., 1996).
Recent clinical trials have shown that a combination treatment
of topical steroid and Vit-D analog (calcipotriol) was more
effective and faster acting than calcipotriol alone (Douglas
et al., 2002; Kragballe and van de Kerkhof, 2006). Vit-D and
its analogs have been found to be effective in treating
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psoriasis, but not all patients respond to therapy and some
developed local irritation to the vitamin D analogs (Mason
et al., 2009; Murphy and Reich, 2011). Therefore, there
continues to be a need to develop more potent vitamin D
analogs with less potential side effects.
The functions of Vit-D are mediated by the interaction of
vitamin D receptor (VDR) with retinoid X receptor that binds
to specific vitamin D response elements (VDRE) in the
promoter region of target genes, resulting in the inhibition
of proliferation and stimulation of differentiation (Bikle,
2004; Dusso et al., 2005). Recently, analogs of Vit-D
and its prehormonal form (25-hydroxyvitamin D3), 1a,25-
dihydroxyvitamin D3–3-bromoacetate (BE) and 25-hydroxyvi-
tamin D3-3-bromoacetate (25-OHD3-3-BE), respectively,
have been developed (Ray et al., 1996). These analogs
covalently attach to VDR and induce conformational
changes in it, resulting in enhanced stability of the VDR–
VDRE complex and stimulation of 24-OHase promoter activ-
ity and its mRNA expression (Ray et al., 1996; Swamy et al.,
2000). These analogs have shown better efficacy as
antiproliferative agents compared with Vitamin D in
keratinocytes (Chen et al., 1999) and in human cancer cell
lines, including prostate cancer (Chen et al., 1999; Swamy
et al., 2003, 2004; Lambert et al., 2007), kidney cancer
(Lambert et al., 2010), pancreatic cancer (Persons et al.,
2010), and neuroblastoma (Lange et al., 2007).
In this context, we demonstrated the antipsoriatic effect of
BE compared with Vit-D in a reconstructed human epidermal
model (RHE) of IL-22-induced psoriasis, and also studied the
putative molecular mechanism underlying this antipsoriatic
effect. We observed that BE is more potent than the same dose
of Vit-D in reverting the psoriasiform changes induced by IL-
22 in the RHE model. Mechanistically, the antipsoriatic effect
of BE was linked to the induction of apoptosis of NHEKs and
decreased phosphorylation of AKT (serine/threonine protein
kinase), mTOR (mammalian target of rapamycin), and p70S6K
(p70S6 kinase) proteins. This antipsoriatic effect of BE was
coupled to the inhibition of IL-22-induced gene expression of
IL-8, RANTES (regulated upon activation, normal T-cell
expressed and secreted), and S100A7 (S100 calcium-binding
protein A7/psoriasin).
RESULTS
BE is a more potent antiproliferative agent for NHEKs compared
with Vit-D
In MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assays, both BE and Vit-D showed significant
antiproliferative effects compared with media (0.84±0.04
vs. 1.81±0.12, Po0.001 and 1.26±0.10 vs. 1.81±0.12,
Po0.05, respectively). However, BE was a significantly more
potent antiproliferative than Vit-D (Po0.05; Figure 1a). In a
carboxy fluorescein succinimidyl ester (CFSE) dilution assay,
proliferation of NHEKs in terms of percentage of divided
cells was significantly reduced with BE and Vit-D compared
with media (17.57±1.04 vs. 34.11±0.59, Po0.001 and
25.93±0.69 vs. 34.11±0.59, Po0.05, respectively). BE
showed a significantly greater antiproliferative effect than
Vit-D here as well (Po0.05) (Figure 1b and c).
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Figure 1. BE (1a,25-dihydroxyvitamin D3-3-bromoacetate) is a more potent antiproliferative agent than Vit-D (1a,25-dihydroxyvitamin D3). Normal human
epidermal keratinocytes (NHEKs) were cultured in the presence or absence of either Vit-D (10 6 M) or BE (106 M) for 5 days. Cell proliferation was measured
by (a) MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay (results are expressed as mean±SEM of optical density (OD), showing
BE to be more antiproliferative than Vit-D) (b) and also by carboxy fluorescein succinimidyl ester (CFSE) dilution assay using flow cytometry (results are expressed
as percent divided cells). Data were analyzed using the FlowJo software. (c) A representative CFSE dilution assay result of untreated (Media), Vit-D-treated,
and BE-treated NHEKs. Both MTT and CFSE dilution assays were repeated 10 times, and each experiment was performed in triplicate. Nonparametric unpaired
test (Mann–Whitney U-test) was performed to determine statistical significance.
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BE regulates keratinocyte proliferation by inhibiting
phosphorylation of the AKT/mTOR pathway
Vit-D and BE significantly decreased the levels of phosphory-
lated AKT (pAKT) in terms of relative intensity compared
with media (0.53±0.007 vs. 1, Po0.05 and 0.22±0.04 vs. 1,
Po0.01, respectively) in NHEKs. Similar results were
observed with pmTOR and its downstream protein p70S6k.
Expression of phosphorylated mTOR (pmTOR) was signifi-
cantly decreased by Vit-D and BE treatment as compared
with media (0.54±0.01 vs. 1, Po0.05 and 0.11±0.02 vs. 1,
Po0.01, respectively). Moreover, there was decreased expres-
sion of p70S6k with Vit-D and BE treatment (0.53±0.008 vs.
1, Po0.05 and 0.21±0.01 vs. 1, Po0.01). BE showed a
significantly more inhibitory effect than Vit-D in phosphoryla-
tion of AKT (Po0.05), mTOR (Po0.05), and p70S6k (Po0.05;
Figure 2a and b).
BE induces apoptosis of keratinocytes more effectively than Vit-D
Our analysis showed that almost 75% (75.75±8.19) of
NHEKs were alive in the untreated group (media) and that
BE induced apoptosis in B55% (54.67±0.88%) and Vit-D
induced apoptosis in 43% (43±0.72%) of the cells (Figure 3a
and b). BE induced apoptosis more significantly than Vit-D
(P¼ 0.03) at the same dosage levels.
BE inhibits IL-22-induced psoriatic changes in the RHE model:
inhibits epidermal proliferation, and induces keratinocyte
differentiation
In cultured RHE tissues, histological examination of untreated
control (media) tissues showed a keratinized, multistratified
epithelium with intact basal, spinous, granular, and cornified
layers (Figure 4a). IL-22 induced characteristic features of pso-
riasis such as increased epidermal thickness (115±3.27mm
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Figure 2. Antiproliferative effect of BE (1a,25-dihydroxyvitamin D3-3-bromoacetate) on keratinocytes is mediated by inhibiting the phosphorylation of the
serine/threonine protein kinase/mammalian target of rapamycin (AKT/mTOR) pathway. Keratinocytes were cultured with media containing Vit-D (1a,25-
dihydroxyvitamin D3; 106 M) or BE (106 M) for 5 days at 37 1C. (a) A representative western blot of six experiments showing that BE and Vit-D inhibited
the phosphorylation of AKT (pAKT), mTOR (pmTOR), and S6kinase (p70S6K). TmTOR, total mTOR. (b) A bar diagram showing relative intensity (adjusted
with a-tubulin) of pAKT, pmTOR, and p70S6k in normal human epidermal keratinocytes (NHEKs). Results are expressed as mean±SEM. Nonparametric
unpaired test (Mann–Whitney U-test) was performed to determine statistical significance. BE showed a significantly more inhibitory effect than Vit-D,
*Po0.05; **Po0.01.
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Figure 3. BE (1a,25-dihydroxyvitamin D3-3-bromoacetate) induced apoptosis on keratinocytes more effectively than Vit-D (1a,25-dihydroxyvitamin D3).
Normal human epidermal keratinocytes (NHEKs) were cultured with or without either Vit-D (106 M) or BE (106 M) for 5 days. Staurosporine (1mM) was
used as a positive control. Cells were stained with allophycocyanin (APC)-conjugated Annexin V for 15 minutes, followed by propidium iodide before data
acquisition in a flow cytometer. Data analyses were performed using the FlowJo software. (a) A representative dot plot showing the percentage of apoptotic cells
with different treatments (Vit-D, BE, and Staurosporine) as compared with untreated control (Media). Six experiments were conducted in triplicate. (b) A bar
diagram showing the percentage of apoptotic cells with different treatments (Vit-D, BE, and Staurosporine). Results are expressed as mean±SEM. Nonparametric
unpaired test (Mann–Whitney U-test) was performed to determine statistical significance.
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vs. 52.50±4.53mm, Po0.001) and hypogranulosis. Vit-D and
BE significantly reverted the IL-22-induced epidermal thicken-
ing (115±3.27mm vs. 48.75±2.26mm, Po0.001 and
115±3.27mm vs. 40±2.67mm, Po0.001, respectively) and
also increased the granular layer of the epidermis. BE was
found to be more antiproliferative than an equimolar dose of
Vit-D (Po0.05) in this model. We also observed that the
number of cells returning in the granular layer of the epidermis
with BE treatment were more than that observed with Vit-D
treatment (Figure 4a). Furthermore, we observed that IL-22
induced increased expression of keratinocyte proliferation
marker, cytokeratin 16 (CK16) (Figure 4b), and decreased
expression of keratinocyte differentiation marker CK10
throughout the noncornified epidermis as compared with
media (Figure 4c). Our findings show that Vit-D and BE effec-
tively reduced this IL-22-induced CK16 expression and
brought back lost differentiation (CK10) in RHE tissues
(Figure 4b and c). BE had a stronger effect on cellular
differentiation and proliferation as compared with Vit-D.
Immunohistochemical staining intensities of both CK16 and
CK10 are given in Table 1.
BE downregulates epidermal genes associated with the
pathogenesis of psoriasis: inhibits mRNA transcriptions
of chemokines (IL-8 and RANTES) and psoriasin (S100A7) in
IL-22-treated RHE tissue
In IL-22-treated RHE tissue, the relative gene expression of
RANTES, IL-8, and psoriasin (S100A7) was significantly
upregulated by almost 27-fold (26.96±0.45), 32-fold (31.54±
1.21), and 92-fold (92.40±1.806), respectively, as compared
with untreated control (media) (Figure 5 d–f). BE significantly
reduced IL-22-induced mRNA expression of RANTES (1.46±
0.14), IL-8 (3.73±0.27), and S100A7 (5.88±0.31) as com-
pared with IL-22. Vit-D at the same dose significantly reduced
the gene expression of RANTES (2.72±0.34), IL-8 (9.403±
0.98), and S100A7 (13.85±0.63) compared with IL-22.
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Figure 4. In the reconstructed human epidermis (RHE) model, BE (1a,25-dihydroxyvitamin D3-3-bromoacetate) inhibited IL-22-induced psoriatic changes.
Images (original magnification  20) are representative of results from six experiments conducted in triplicate. (a) Hematoxylin and eosin (H&E) staining of RHE
tissue sections showed IL-22-induced epidermal hyperplasia (double-headed arrows) and hypogranulosis (arrowheads). Vit-D (1a,25-dihydroxyvitamin D3) and BE
significantly reverted these effects. (b) Immunohistochemical staining showed that Vit-D and BE significantly decreased IL-22-induced cytokeratin 16 (CK16)
staining intensity. (c) IL-22 decreased CK10 staining intensity, which was reversed with Vit-D and BE treatment. (d) Negative control without primary antibody.
(e) Bar diagram showing changes in epidermal thickness measured in viable cell layers, excluding the stratum corneum, with different treatments (IL-22, Vit-D,
and BE). Mann–Whitney U-test was performed to determine statistical significance.
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The effect of BE was found to be more significant than Vit-D in
reducing IL-22-induced RANTES (Po0.05), IL-8 (Po0.05),
and S100A7 (Po0.05) expression.
BE reduces IL-22-induced gene expression of AKT1 and MTOR,
confirming one of the mechanisms underlying its
antiproliferative effect
In RHE culture, we found that IL-22 significantly upregulated
expression of MTOR by 35-fold (34.54±1.06) and AKT1 by
25-fold (25.31±2.44), as compared with untreated control. BE
significantly reduced IL-22-induced mRNA expression of
MTOR (2.86±0.25) and AKT1 (2.44±0.31), as compared
with IL-22. Vit-D at the same dose level significantly reduced
IL-22-induced gene expression of MTOR (6.19±0.53) and
AKT1 (5.29±0.59). We also found that BE had a stronger
effect in reducing the expression of MTOR and AKT1 than
Vit-D (Po0.05 and Po0.05, respectively).
DISCUSSION
To the best of our knowledge, we report that a previously
unreported vitamin D analog, BE, is a significantly stronger
antipsoriatic agent than equimolar amounts of Vit-D in
reverting IL-22-induced psoriasis in the RHE model.
Physiological and pharmacological actions of 1,25-
(OH)2D3 in various systems, together with the identification
of VDR in target cells, have indicated potential therapeutic
applications of VDR ligands in inflammation and dermatolo-
gical indications such as psoriasis, actinic keratosis, seborrheic
dermatitis, photoaging, osteoporosis, cancers, and autoim-
mune diseases (Nagpal et al., 2005). Interaction of BE with
VDR results in rapid covalent labeling of VDR in
keratinocytes, which caused the conversion of apo-VDR to a
holoform with a more diverse conformation than that of the
1,25(OH)2D3–VDR complex, resulting in improved stability
of the 1,25(OH) 2D3-3-BE/VDR–VDRE complex (Swamy
et al., 2000) and probably contributing to the amplified
antiproliferative effect of BE in keratinocytes than Vit-D.
Our main focus was to evaluate the potency of BE in
psoriasis, for which we used the RHE model. RHE comprises
Table 1. Immunohistochemistry staining intensities
CK16 CK10
Treatment (mean±SEM) (mean±SEM)
Media 162.3±1.94 91.75±1.30
IL-22 97.9±1.87* 166.9±2.50*
IL-22þVit-D 166.8±2.45# 111.3±1.89#
IL-22þBE 185.5±2.28#,$ 93.2±0.99#,$
Abbreviations: BE, 1a,25-dihydroxyvitamin D3-3-bromoacetate; CK, cyto-
keratin; Vit-D, 1a,25-dihydroxyvitamin D3.
*Po0.01 compared with media of the same group; #Po0.01 compared
with IL-22 of the same group; $Po0.05 compared with IL-22þVit-D of the
same group; Mann–Whitney U-test. Higher values indicate less staining
intensity.
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Figure 5. BE (1a,25-dihydroxyvitamin D3-3-bromoacetate) and Vit-D (1a,25-dihydroxyvitamin D3) inhibited IL-22-induced gene expression of mammalian
target of rapamycin (MTOR), serine/threonine protein kinase 1 (AKT1), chemokines (IL-8 and RANTES (regulated upon activation, normal T-cell expressed and
secreted)), and S100A7 (S100 calcium-binding protein A7 or psoriasin) in the reconstructed human epidermis (RHE) model. Bar diagrams are representative of
results from six experiments conducted in triplicate. Results are expressed in mean±SEM. (a) Representative profile of the extracted total RNA from RHE samples
with or without IL-22, Vit-D, and BE treatments in agarose gel (1.5%) electrophoresis. Bands correspond to 28S and 18S rRNA. (b, c) Relative changes in
gene expression of AKT1 and MTOR, respectively, in IL-22-treated RHE with Vit-D or BE treatment. (d–f) Relative changes in gene expression of IL-8, RANTES,
and S100A7, respectively, in IL-22-treated RHE with Vit-D or BE treatment. Mann–Whitney U-test was performed to determine statistical significance.
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multilayered epidermis consisting of basal, spinous, granular,
and cornified layers, analogous to those found in vivo.
Previous studies showed that keratinocytes express functional
receptors for IL-22 (Boniface et al., 2005) and IL-22-
upregulated proinflammatory gene expression in
keratinocytes. It has also been demonstrated that psoriatic
pathology can be induced in the RHE model by IL-22
(Boniface et al., 2005; Sa et al., 2007). Keeping this in
mind, we used IL-22 to induce psoriasiform changes in the
RHE tissue. In this model, we demonstrated that BE reduced
the thickness of the hyperplastic epidermis induced by IL-22
and also increased the differentiation of different layers of the
epidermis more effectively than the same dose of Vit-D.
mTOR has emerged as a major effector of cell growth and
proliferation via regulation of protein synthesis (Hay and
Sonenberg, 2004). The critical regulator of mTOR is AKT, a
serine/threonine kinase, which is activated by nutrients and
growth factors in a phosphatidylinositol 3 kinase–dependent
manner (Gills and Dennis, 2004; Morgensztern and McLeod,
2005). Phosphorylation of S6K, the downstream protein of
mTOR, regulates cell growth via increased mRNA
translation (Montagne et al., 1999; Radimerski et al., 2002).
The mechanism underlying the antiproliferative effect
of BE was found to be the inhibition of the phosphorylation
of AKT, mTOR, and its downstream signaling protein
S6K in NHEKs. To further confirm this, real-time PCR was
performed on total RNA isolated from RHE tissue treated with
IL-22 with or without Vit-D and BE. We found that BE more
significantly reduced IL-22-induced mRNA expression of
AKT1 and MTOR in RHE model than Vit-D, thereby
confirming regulation of AKT/mTOR pathway behind its
antiproliferative effect.
The mechanism for the antimitotic effect of Vit-D is quite
complex. In prostate cancer, it causes cell cycle arrest
(Zhuang and Burnstein, 1998), whereas in osteosarcoma cell
line (Thompson et al., 2012), psoriatic keratinocytes
(Tiberio et al., 2009), and in colon cancer cell lines (Dı´az
et al., 2000) it induces apoptosis. Exploration of the
antiproliferative effect of BE indicates that BE significantly
induced apoptosis in NHEKs, which might account for its
antiproliferative effect.
S100A7 (psoriasin) belongs to a group of calcium-binding
proteins, involved in antimicrobial defense, chemotaxis, and
epidermal differentiation complex (Ryckman et al., 2003;
Sa et al., 2007). Previous reports demonstrate that high levels
of IL-22 in psoriatic skin were associated with the upregulation
of psoriasin (Wolk et al., 2006), and it is overexpressed in
psoriatic lesions (Peric et al., 2009). We demonstrated that BE
has a significant effect in reducing the IL-22-induced gene
expression of psoriasin. The effect of BE was stronger than
Vit-D, thus establishing its better antipsoriatic role than Vit-D.
RANTES (Raychaudhuri et al., 1999) and IL-8 (van Beelen
et al., 2007) have a critical role in the pathogenesis of
psoriasis, and it has been reported that IL-22 is capable of
inducing these genes in keratinocytes (Boniface et al., 2005;
Wolk et al., 2006; Sa et al., 2007). Topical treatment with
Vit-D and its analogs decreased the production of RANTES
and IL-8 levels (Fukuoka et al., 1998; van Beelen et al., 2007).
We found that BE inhibited the IL-22-mediated induction of
these chemokines in the RHE model.
Our study illustrated that BE strongly suppressed the pro-
liferation of NHEKs by inhibiting AKT/mTOR signaling and
inducing apoptosis in these cells. This antiproliferative effect
of BE is not confined to a monolayer of NHEKs; it also reduced
the proliferation induced by IL-22 in a multilayered recon-
structed human epidermis resembling psoriasis in vivo. More-
over, BE was highly effective in reverting the IL-22-induced
gene expression profiles of chemokines (RANTES and IL-8),
which have an important pathogenic role in psoriasis. It also
inhibited the altered differentiation process of keratinocytes, as
evidenced by the suppression of IL-22-induced gene expres-
sion of S100A7 in the RHE. All the effects of BE were stronger
than the effects of the same dose of Vitamin D. Considered
together, our results have important implications in future
antipsoriatic treatment, and further preclinical and clinical
studies of BE are required for its establishment as a potent
antipsoriatic agent.
MATERIALS AND METHODS
Materials
BE and Vit-D are supplied by Dr Rahul Ray (Vitamin D, Skin and
Bone Research Laboratory, Boston University School of Medicine,
Boston, MA). The dose of Vit-D and BE was standardized to 10 6 M
and used for all experiments. All other chemicals were purchased
from Sigma-Aldrich (St Louis, MO) if not mentioned separately.
Cell culture
NHEKs were obtained from normal individuals undergoing plastic
surgery (n¼ 10), according to the standardized protocol (Normand
and Karasek, 1995). Cells were cultured in keratinocyte basal
medium supplemented with growth factors, hormones, and anti-
biotics (KGM-Gold SingleQuots, Lonza Walkersville, MD), hence-
forth mentioned as KGM. Cells at third to sixth passage were used for
subsequent experiments.
Cell proliferation assays
Cell proliferation was measured by MTT assay and CFSE dilution
assay.
MTT assay. 2 104 NHEKs per well were seeded in triplicate in
24-well culture plates with KGM in the presence or absence of
Vit-D and BE and incubated for 5 days at 37 1C in humidified 5%
CO2 incubator. The MTT assay was performed according to our
standardized protocol (Raychaudhuri et al., 2008).
CFSE dilution assay. NHEKs were incubated with 2mM of CFSE
(Molecular Probes, Eugene, OR) reagent for 15 minutes followed
by washing with phosphate-buffered salineþ 0.1% BSA (Fisher
BioReagents, Fair Lawn, NJ), and then 1 105 NHEKs per well
were seeded in triplicate in six-well plates with KGM, Vit-D, and
BE. CFSE dilution was assessed by flow cytometry (FACS Calibur,
Becton Dickinson, San Jose, CA), and FACS data analysis was
performed using the FlowJo software (Tree Star, Ashland, OR).
Apoptosis assay
NHEKs were grown up to 70–80% confluence followed by treatment
with Vit-D and BE, and incubated overnight at 37 1C. Staurosporine
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(1mM; Cell Signaling Technology, Danvers, MA)-induced apoptosis
was used as a positive control (Roeder et al., 2011; Yao et al., 2011).
At the end of incubation, cells were collected and washed in
phosphate-buffered saline with 2% fetal bovine serum (Axenia
Biologix, Dixon, CA) and 2.5 mM CaCl2, and then incubated in ice
with allophycocyanin-conjugated Annexin V (BD Pharmingen, San
Diego, CA). Propidium iodide (BD Pharmingen) was added just
before data acquisition in the flow cytometer (FACS Calibur). Data
were analyzed using the FlowJo software.
Western blot analysis of pAKT, pmTOR, and p70S6k in NHEKs
NHEKs were grown until 70–80% confluence and were serum-
starved for 24 hours, followed by the addition of Vit-D or BE and
incubation overnight at 37 1C. Cell lysates were prepared according
to our standardized protocol (Raychaudhuri et al., 2012). An equal
amount of protein (30mg) for each lysate was subjected to 10% (for
pAKT, p70S6k, and a-tubulin) and 6% (for pmTOR and total mTOR)
SDS-PAGE. We used p70S6k at 1:200 dilution, pAKT (Ser473) at 1:250
dilution, and a-tubulin at 1:500 dilution for 10% membrane
consecutively, and pmTOR (Ser2448) at 1:200 dilution and total
mTOR at 1:500 dilution for 6% membrane. The membrane was
then washed and incubated with a 1:5,000 dilution of peroxidase-
conjugated goat anti-rabbit IgG Fc Fragment–Specific antibody
(Jackson Immunoresearch Labs, West Grove, PA) for 1 hour. Primary
antibodies were purchased from Cell Signaling Technology. The
bands were analyzed for their density using the Image J software
(NIH, Bethesda, MD). Results were expressed as relative intensity
(intensity of each band was adjusted to that of a-tubulin).
RHE model
EpiDerm RHE tissue and EPI-100-NMM medium were purchased
from MatTek (Ashland, MA). In six-well plates, three tissues per
treatment condition were cultured at the air–liquid interface for 4
days in 5 ml of medium in the presence or absence of Vit-D, BE, and
human recombinant IL-22 (30 ng ml 1) (eBioscience, San Diego, CA)
alone or in combination. The medium was changed every alternate
day with fresh treatments. On day 5, tissues were collected and
divided in two halves, one half was snap-frozen in liquid nitrogen for
histology and another half was used for real-time PCR study. For
histology studies, 8-mm sections were used. The sections were stained
with hematoxylin and eosin (American Master Tech Scientific, Lodi, CA),
according to our standardized protocol (Raychaudhuri et al., 2004).
For immunohistochemistry, 8-mm tissue sections on glass slides
were air-dried and fixed in ice-cold acetone (American Master Tech
Scientific), followed by blocking with 10% BSA. The tissues were
then incubated overnight at 4 1C with primary antibody, either
anticytokeratin 16 (CK16; clone: LL025) or anticytokeratin 10
(CK10; clone: DE-K10). Primary antihuman mouse mAbs for immu-
nohistochemistry were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). On the following day, tissues were washed with
phosphate-buffered saline and 0.1% Tween, followed by incubation
with biotinylated horse antimouse secondary antibody, Vectastain
ABC Elite reagents, and metal-enhanced diaminobenzidine (DAB).
Next, the tissues were counterstained with Toluidine blue and
mounted for bright-field viewing. The secondary antibody, ABC elite
reagents, and DAB were purchased from Vector Laboratories
(Burlingame, CA). Epidermal thicknesses of hematoxylin and
eosin–stained tissues were measured using a light microscope at
 20 with an eyepiece micrometer, taking four measurements
for each tissue across the subcorneal cell layers. For immuno-
histochemistry staining intensity, histology images were analyzed
using Adobe Photoshop CS4 extended version 11.0.1 (Adobe
Systems, San Francisco, CA) image analysis software, according to
the standardized protocol (Lehr et al., 1997; Lahm et al., 2004).
Higher values indicate less staining intensity. Mean epidermal
thickness and mean intensity values were calculated per tissue and
for each treatment group.
Quantitative real-time PCR
RHE tissues were collected and homogenized, and total cellular RNA
was isolated using TRIzol reagent (Life Technologies, Green Island,
NY) according to the manufacturer’s instructions. The amount and
quality of mRNA were determined using a Biomate 3 UV-Vis
Spectrophotometer (Thermo Electron Scientific Instruments, Madison,
WI) and 1.5% agarose gel electrophoresis. According to the manu-
facturer’s protocol, 1mg of template RNA was then reverse-tran-
scribed to complementary DNA using the Omniscript RT kit, RNase
Inhibitor from Qiagen (CA), and oligo dT primers (Oligo peptide
primers, Fermentas, Waltham, MA). Quantitative real-time PCR was
conducted in the ABI 7500 Fast RT PCR system (Applied Biosystems,
CA) using SYBR green (RT SYBR Green ROX Fast Master Mix;
Qiagen, Valencia, CA) and specific primers for MTOR, AKT1, IL-8,
RANTES, and S100A7. The primers were designed using Primer
Express Software Version 3.0 (Applied Biosystems, Foster City, CA)
and Primer 3Plus (http://www.bioinformatics.nl/cgi-bin/primer3plus/
primer3plus.cgi) and were synthesized by Invitrogen (Green Island,
NY). The primer sequences are as follows: IL-8 forward sequence
50-AGGTGCAGTTTTGCCAAGGA-30 and reverse sequence 50-TTTC
TGTGTTGGCGCAGTGT-30; RANTES forward sequence 50-TCCTGC
AGAGGATCAAGACA-30 and reverse sequence 50-CAATGTAGG-
CAAAGCAGCAG-30; S100A7 forward sequence 50-CTTCTACTCGT
GACGCTTCC-30 and reverse sequence 50-AATTTGTGCCCTTTTT
GTCA-30; AKT1 forward sequence 50-GACGGGCACATTAAGAT
CAC-30 and reverse sequence 50-TGAGGATGAGCTCAAAAAGC-30;
MTOR forward sequence 50-ATTTGATCAGGTGTGCCAGT-30 and
reverse sequence 50-GCTTAGGACATGGTTCATGG-30; RN18S1 for-
ward sequence 50-TCAAGAACGAAAGTCGGAGG3-30 and reverse
sequence 50-GGACATCTAAGGGCATCACA-30. Cycling conditions
comprised initialization step for 10 minutes at 95 1C, followed by
two-step PCR for 40 cycles of 95 1C for 10 seconds (denaturation) and
60 1C for 30 seconds (annealing/extension). Data were collected at the
end of the 60 1C annealing/extension step. Amplification reactions
were performed in triplicate for each sample, and analysis of relative
gene expression data, normalized to endogenous control (RN 18S1),
was calculated using RQ¼ 2DDCT method on an ABI 7500 Fast RT
PCR system Software (Applied Biosystems).
Statistical analysis
Experiments were conducted in triplicate. Results were expressed as
mean±SEM. Statistical analyses to determine the differences in cell
proliferation, apoptosis, protein expression, gene expression, immu-
nohistochemistry intensity, and epidermal thickness measurements
between different treatment groups were performed using the Graph-
Pad Prism software, version 5.0 (GraphPad Software, San Diego, CA).
Nonparametric unpaired test (Mann–Whitney U-test) was used to
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determine statistical significance. The P-value of o0.05 was con-
sidered to be statistically significant.
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